Grade My Investments
HomeFree Stock Grades › IDYA

IDEAYA Biosciences, Inc. (IDYA) Stock Grade

IDYA · Healthcare

A+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$3.1B
P/E Ratio
Revenue Growth (YoY)
+3024.4%
Net Margin
-52.0%
Return on Equity
Dividend Yield
None

About IDEAYA Biosciences, Inc.'s fundamentals

IDEAYA Biosciences is a biotechnology company with a market capitalization of $3.1 billion that reported exceptional revenue growth of 3,024% year-over-year, indicating rapidly expanding commercial activity. However, the company operates at a significant loss with a net margin of -52%, meaning it spends substantially more than it generates in revenue. As a pre-profitability biotech firm, IDEAYA does not pay dividends and reported a net loss in its latest annual statement, which is typical for companies in early-stage commercialization phases focused on research and development investments.

Track IDYA free — no credit card required. Live grade + monthly AI report →